[en] BACKGROUND: Arzoxifene is a selective estrogen receptor modulator (SERM) more potent in preclinical testing than currently available agents. Its effects on clinical outcomes are not known. METHODS: In a randomized blinded trial, women age 60 to 85 years with osteoporosis, defined as a femoral neck or lumbar spine bone mineral density T-score less than or equal to -2.5 or a vertebral fracture, and women with low bone mass, defined as a bone density T-score less than or equal to -1.0 and above -2.5, were assigned to arzoxifene 20 mg or placebo daily. The primary endpoints were new vertebral fracture in those with osteoporosis, and invasive breast cancer in the overall population. RESULTS: After 3 years, the cumulative incidence of vertebral fractures in patients with osteoporosis was 2.3% lower in the arzoxifene than in the placebo group, a 41% relative risk reduction (95% CI 0.45 to 0.77; P<0.001). In the overall population, the cumulative incidence of invasive breast cancer over 4 years was reduced by 1.3%, with a 56% relative reduction in risk (HR=0.44; 95% CI 0.26 to 0.76; P<0.001); there was no significant decrease in nonvertebral fracture risk. Arzoxifene increased the cumulative incidence of venous thromboembolic events by 0.7%, with a 2.3-fold relative increase (95% CI 1.5 to 3.7). CONCLUSION: Like other SERMs, arzoxifene decreased vertebral fractures and invasive breast cancer while the risk of venous thromboembolic events increased. (c) 2010 American Society for Bone and Mineral Research.
Disciplines :
General & internal medicine
Author, co-author :
Cummings, S. R.
McClung, M.
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Cox, D.
Mitlak, B.
Stock, J.
Amewou-Atisso, M.
Powles, T.
Miller, P.
Zanchetta, J.
Christiansen, C.
Language :
English
Title :
Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
Publication date :
February 2011
Journal title :
Journal of Bone and Mineral Research
ISSN :
0884-0431
eISSN :
1523-4681
Publisher :
American Society for Bone and Mineral Research, Washington, United States - District of Columbia
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998; 90: 1371-1388.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999; 282: 637-645.
Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006; 355: 125-137.
Palkowitz AD, Glasebrook AL, Thrasher KJ, et al. Discovery and synthesis of [6-hydroxy-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-2-(4-hydroxyphenyl)] benzothiophene: a novel, highly potent, selective estrogen receptor modulator. J Med Chem. 1997; 40: 1407-1416.
Zanchetta J, Palacios S, Cox D, Stock J, Dowsett S, Kendler D., Arzoxifene versus raloxifene: 12-month effects on bone mineral density, bone turnover markers, and safety parameters in postmenopausal women with osteoporosis. Osteoporos Int. 2009; 20 (Suppl 1): S14.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Womens Health Initiative randomized controlled trial. JAMA. 2002; 288: 321-333.
Gennari L, Merlotti D, Valleggi F, Martini G, Nuti R., Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging. 2007; 24: 361-379.
Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008; 359: 697-708.
Genant HK, Wu CY, van KC, Nevitt MC., Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993; 8: 1137-1148.
Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003; 18: 1947-1954.
Mackey DC, Lui LY, Cawthon PM, et al. High-trauma fractures and low bone mineral density in older women and men. JAMA. 2007; 298: 2381-2388.
Kurman RJ, Norris HJ., Endometrial hyperplasia and related cellular changes. In:, Kurman RJ, ed. Blausteins Pathology of the Female Genital Tract. 4th ed. New York: Springer-Verlag; 1994: 411-427.
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999; 281: 2189-2197. Erratum in JAMA 1999;282:2124.
Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23: 1923-1934.
Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010; 362: 686-696.
Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Womens Health Initiative randomized trial. JAMA. 2003; 290: 1729-1738.
Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause. 2009; 16: 1109-1115.
Barrett-Connor E, Grady D, Sashegyi A, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA. 2002; 287: 847-857.
Ivanova MM, Mazhawidza W, Dougherty SM, Minna JD, Klinge CM., Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells. Mol Cell Endocrinol. 2009; 305: 12-21.
Vegeto E, Cuzzocrea S, Crisafulli C, et al. Estrogen receptor-alpha as a drug target candidate for preventing lung inflammation. Endocrinology. 2010; 151: 174-184.
Cirillo DJ, Wallace RB, Rodabough RJ, et al. Effect of estrogen therapy on gallbladder disease. JAMA. 2005; 293: 330-339.